Trial reportDrug and alcohol dependence2015
Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
Trial report in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Alcohol Pharmacotherapy for HIV+ Prisoners With Alcohol Dependence and Problem Drinking
Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Extended-release injectable naltrexone for opioid use disorder: a systematic review.Addiction (Abingdon, England) · 2018Pooled it
- Leveraging the U.S. Criminal Justice System to Access Women for HIV Interventions.AIDS and behavior · 2017Pooled it
- Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.Journal of substance abuse treatment · 2022Trial
- Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.Substance abuse · 2021Trial
- Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.Journal of substance abuse treatment · 2018Trial
- Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.Drug and alcohol dependence · 2017Trial
- Injectable pharmacotherapy for opioid use disorders (IPOD).Contemporary clinical trials · 2016Trial
- Continuity of Prescription Medication Use Among Adults Leaving State Prison.JAMA network open · 2025Article
- The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV.Drug and alcohol dependence reports · 2023Article
- Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.BMC public health · 2022Article
- Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.Campbell systematic reviews · 2022Article
- Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.Journal of substance abuse treatment · 2020Article
- Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support.Journal of substance abuse treatment · 2019Article
- Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.The American journal on addictions · 2018Review
- A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.Journal of substance abuse treatment · 2018Article
- Barriers to initiation of extended release naltrexone among HIV-infected adults with alcohol use disorders.Journal of substance abuse treatment · 2018Article
- Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.Drug and alcohol dependence · 2017Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundThe acceptability of and retention on extended-release naltrexone (XR-NTX), an FDA-approved medication for the treatment of alcohol and opioid use disorders, among persons living with HIV disease (PLH) under criminal justice setting (CJS) supervision has not been evaluated to date.
methodsTwo double-blind placebo-controlled randomized trials of XR-NTX for inmates with HIV disease transitioning to the community with (1) alcohol use disorders (AUDs) or (2) opioid use disorders, are underway. Reasons for not accepting XR-NTX and an evaluation of differences in demographic features between those who were retained on study drug and those who did not return for their second injection post-release are discussed.
results70% of eligible persons consented to participate; almost 90% received their first injection; and almost 60% returned for their first injection after release. Variables found to be associated (p<0.10) with returning for the second injection included: not meeting criteria for hazardous drinking (p=0.035; OR 0.424 (CI 0.191-0.941)); being prescribed antiretroviral therapy (p=0.068; OR 2.170 (CI 0.943-4.992)); expressing experiencing serious depression 30 days prior to incarceration (p=0.068; OR 1.889 (CI 0.955-3.737)); not having a positive cocaine urine screen on the day of release (DOR) (p=0.011; OR 0.258 (CI 0.091-0.729)); and not meeting criteria for an AUD plus any substance use disorder (p=0.068; OR 0.521 (CI 0.259-1.048)). Only positive cocaine urine test on DOR was statistically significant after multivariate regression analyses (p=0.005; OR 0.207 (CI 0.068-0.623)).
conclusionCJS based XR-NTX programs are highly acceptable among PLH, however retention on XR-NTX after release is negatively impacted by relapse to cocaine use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.